Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Rasna Therapeutics, Inc. (OTC: RASP).

Full DD Report for RASP

You must become a subscriber to view this report.


Recent News from (OTC: RASP)

Rasna's Act D shows positive effect in mid-stage AML study, OM still an issue
Updated results from a Phase 2 clinical trial assessing Rasna Therapeutics' ( OTCQX:RASP ) lead candidate actinomycin D (Act D) in patients with NPM1 mutation-positive acute myeloid leukemia (AML) showed a treatment effect. More news on: Rasna Therapeutics, Inc., Healthcare stocks news,...
Source: SeekingAlpha
Date: January, 03 2018 11:32
Rasna Therapeutics, Inc., Announces Follow Up Phase II Clinical Data Confirming Efficacy of Actinomycin D in Patients with NPM1-Mutated Acute Myeloid Leukemia
Treatment with Actinomycin D (Act D) as a single drug achieved complete remission in 4 out of 9 evaluable patients (44.4%). Treatment with Act D at 15 µg/kg/day for 5 days every 28 days (which defines one cycle) was well tolerated with major toxicity limited only to oral mucos...
Source: Business Wire
Date: January, 03 2018 10:46
Rasna Therapeutics, Inc. Advances Development of a Novel Treatment for NPM1-mutated Acute Myeloid Leukemia
Rasna Therapeutics, Inc. (OTCQX:RASP), a clinical stage biotechnology company focused on the development of disease-modifying drugs for hematological malignancies, today provided an update from further studies towards the development of formulated RASP-101, a novel modality for treatment of ...
Source: Business Wire
Date: May, 08 2017 08:19
Now Introducing Rasna Therapeutics
Rasna Therapeutics (RASP), headquartered in New York City, is a new and widely unknown company formed in 2013. Rasna Therapeutics focuses on the high unmet need seen in acute myeloid leukemia, or AML. The purpose of this article is to get investors aware of this very early, but highly promisin...
Source: SeekingAlpha
Date: May, 01 2017 13:44
Rasna Therapeutics Names Dr. Kunwar Shailubhai As New CEO
Rasna Therapeutics, Inc. (OTCQX:RASP), is pleased to announce the appointment of Dr. Kunwar Shailubhai as Chief Executive Officer. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170420006678/en/ Dr. Kunwar Shailub...
Source: Business Wire
Date: April, 20 2017 18:44
OTC Markets Group Welcomes Rasna Therapeutics to OTCQX
NEW YORK , April 12, 2017 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Rasna Therapeutics, Inc. (OTCQX: RASP), a clinical-stage  biotechnology company focused on delivering novel th...
Source: PR Newswire
Date: April, 12 2017 07:00
Rasna Therapeutics Announces Upgrade to OTCQX®
Rasna Therapeutics, Inc. (OTCQX:RASP), a clinical-stage biotechnology company focused on delivering novel therapeutics and biomarkers for acute myeloid leukemia (AML) patients, today announced it has qualified and is now trading on the OTCQX® Best Market, operated by OTC Markets Group...
Source: Business Wire
Date: April, 12 2017 07:00
Rasna Therapeutics, Inc. Closes Private Placement of $2 Million
Rasna Therapeutics, Inc. (OTCQB:RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced that it has closed a private placement to accredited investors of an aggregate 3,366,667 shares of common stock at $0.60 per share for gross proceeds o...
Source: Business Wire
Date: December, 27 2016 07:16
Rasna Therapeutics, Inc. Appoints Dr Alessandro Padova as Chairman
Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced the appointment of Dr Alessandro Padova as Chairman with immediate effect. “We are delighted to welcome Alessandro to the Rasna team and lo...
Source: Business Wire
Date: October, 18 2016 10:09
Rasna Therapeutics, Inc. Announces Forward Split of Common Stock, Name Change & Ticker Change to RASP
Rasna Therapeutics, Inc. (OTCQB:RASP) (the “Company”) (formerly Active With Me, Inc.), a development stage biotechnology company focused on the development of cancer drugs, today announced it has implemented a 3.25-for-1 forward split of its common stock in effect for trading o...
Source: Business Wire
Date: September, 27 2016 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-14N/A0.80N/AN/A0
2018-08-13N/A0.80N/AN/A0
2018-08-100.800.800.800.801,000
2018-08-090.800.800.800.802,000
2018-08-08N/A1.00N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-101,0001,000100.0000Short
2018-07-319001,00090.0000Short
2018-05-223,1233,123100.0000Short
2018-05-183,5005,21767.0884Short
2018-05-173,59010,00035.9000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RASP.


About Rasna Therapeutics, Inc. (OTC: RASP)

Logo for Rasna Therapeutics, Inc. (OTC: RASP)

Rasna Therapeutics, Inc. OTC:RASP , a development stage biotechnology company focused on the development of cancer drugs, today announced the successful completion of its merger. Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia AML , leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna s focus on inhibition of lysine specific demethylase LSD , an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD regulators that have shown appropriate effects on the LSD gene in vitro and in IND enabling pre clinical studies.

 

Contact Information

 

 

Current Management

  • Kunwar Shailubhai / CEO
    • Dr. Shailubhai is a CoFounder of Synergy Pharmaceuticals Inc. and has served as Chief Scientific Officer since . From March until July he served as Senior Vice President, Drug Discovery, of Synergy which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. Synergy DE . From May until March , Dr. Shailubhai served as Executive Vice President, Research and Development of Synergy DE. From to April , Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of our GCC agonist program for drugs to treat colon cancer and GI inflammation. Between and , he was with Monsanto Company, serving as Group Leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in from the University of Baroda, India, and his M.B.A. in from the University of Missouri, St. Louis.
  • Tiziano Lazzaretti / CFO
  • Alessandro Padova / Chairman, Independent Director
    • Since October , Dr. Padova has served as Chief Executive Officer of Fondazione Ri.MED, a foundation based in Sicily, that promotes, supports and leads biomedical and biotechnological research projects. From July to September , Dr. Padova was Senior Director, Strategy and Business Development and from June to June , Director of Strategic Alliances for IRBM Group in Rome, Italy, a diversified industrial group operating within the biotech and pharmaceutical sector. From May to March , Dr. Padova was held various positions with Siena Biotech S.p.A., a drug discovery and development company, most recently as General Manager. Dr. Padova graduated from University of Kent with a degree in Chemistry and received his Ph.D. in Chemistry from University of Exeter.
  • John P. Brancaccio / Independent Director, Audit Committee Member
    • Since April , Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a director of Callisto Pharmaceuticals, Inc. from April until its merger with Synergy Pharmaceuticals, Inc. in January and has been a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April , as well as a director of Trovagene, Inc. since December , Synergy Pharmaceuticals Inc. since July and ContraVir Pharmaceuticals, Inc. since December .
  • Riccardo DallaFavera / Independent Director, Compensation Committee Member
    • Dr. DallaFavera is a leader in the field of molecular oncology and has made fundamental contributions to the field of cancer, especially in the study of the molecular genetics of B cell malignancies. A Columbia faculty member for more than years, Dr. DallaFavera helped found and has led the Institute for Cancer Genetics at Columbia University since . He is the Percy and Joanne Uris Professor of Pathology and Professor of Genetics amp Development at the Columbia University College of Physicians and Surgeons. He is also a director of the Specialised Center for research on Lymphoma at Columbia University funded by the Leukemia Lymphoma Society. Dr. DallaFavera joined Columbia s College of Physicians and Surgeons in the Department of Pathology in . He completed a fellowship at the National Cancer Institute and was previously a faculty member at New York University School of Medicine. Dr. DallaFavera currently serves as a director of Tiziana Life Sciences plc. Dr. DallaFavera cofounded Therasis, Inc. in and has since served as a director of that company. He has been a member of the Scientific Advisory Board of Trovagene, Inc. since April . He serves as a member of the Scientific Advisory Board of Xigen SA. Dr. DallaFavera was a director of the Herbert Irving Comprehensive Cancer Centre HICCC from to . He has served as the Chair of the Scientific Advisory Board of the Yale Cancer Centre.
  • John Alex Martin / Independent Director
    • Mr. Martin has been Chief Executive Officer of Puricore Inc., a biopharmaceutical company focused on dermatology, ophthalmology, and rare diseases since . From to , Mr. Martin was President of Moksha Pharmaceuticals, Inc., an emerging markets pharmaceutical company. From to , Mr. Martin was Managing Director of The Sophocles Group, a private consulting company. From to , Mr. Martin was Chief Operating Officer of Intercept Pharmaceuticals, Inc. Mr. Martin graduated from Cornell University with a BA degree in Government and received his MBA from Harvard Graduate School of Business Administration.
  • Jim Mervis / Independent Director, Audit Committee Member
    • Mr. Mervis has been Managing Director of Bioscience Strategies NZ Limited, a consulting company, since March . In addition, Mr. Mervis has been Chairman of CoDa Therapeutics, Inc. since and a director of Engender Technologies Ltd. since . Mr. Mervis has been a Senior Advisor to the University of Auckland s technology transfer arm Auckland Uniservices since and the New Zealand government s Return On Science investment committee since . Mr. Mervis has been Senior Advisor to Professor Roberto Pellicciari and his lab TES Pharma since . He was a litigation associate at the New York firm of Rubin Wachtell Baum amp Levin from to . From to , Mr. Mervis held senior executive positions in the pioneering days of cable television, pay television and home video, at Viacom International, Showtime Pay Television, CBS Video Enterprises and MGM/UA Home Entertainment. From to , he was a key business development consultant to Virgin Communications, Childrens Television Workshop, EMI Music, Roy Orbison, Sergio Leone and Island Pictures. In , he cofounded one of the first interactive media companies where he produced the interactive version of Stephen Hawking s A Brief History of Time released . Mr. Mervis obtained his BS from Cornell University in and his JD from Fordham University School of Law in .
  • Kunwar Shailubhai / Independent Director, Compensation Committee Member
    • Dr. Shailubhai is a CoFounder of Synergy Pharmaceuticals Inc. and has served as Chief Scientific Officer since . From March until July he served as Senior Vice President, Drug Discovery, of Synergy which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. Synergy DE . From May until March , Dr. Shailubhai served as Executive Vice President, Research and Development of Synergy DE. From to April , Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of our GCC agonist program for drugs to treat colon cancer and GI inflammation. Between and , he was with Monsanto Company, serving as Group Leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in from the University of Baroda, India, and his M.B.A. in from the University of Missouri, St. Louis.

Current Share Structure

  • Market Cap: $137,816,006 - 03/09/2018
  • Authorized: 200,000,000 - 09/29/2016
  • Issue and Outstanding: 68,908,003 - 11/29/2017
  • Float: 5,866,254 - 09/29/2016

 


Recent Filings from (OTC: RASP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 16 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Proxy Statement - Proxy Statement
Filing Type: Proxy Statement - Proxy StatementFiling Source: OTC Markets
Filing Date: March, 01 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018
Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act
Filing Type: 10-KTFiling Source: edgar
Filing Date: November, 30 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 12 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 31 2017

 

 


Daily Technical Chart for (OTC: RASP)

Daily Technical Chart for (OTC: RASP)


Stay tuned for daily updates and more on (OTC: RASP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RASP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RASP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of RASP and does not buy, sell, or trade any shares of RASP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/